Regeneron Pharmaceuticals, Inc. — Earnings Quality Grade B
REGN · Healthcare
Generally healthy
Screening Summary
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 146 days, change -14 days YoY
AR growth -7.6% vs revenue growth 1.0%
Revenue 1.0%, CFFO 12.6%. Cash follows revenue
Expense Quality
Inventory 3.7% vs COGS 6.6%. Normal
CapEx growth 37.7% is >2x revenue growth 1.0%
SG&A/Gross Profit = 22.1%, excellent (<30%)
Gross margin 85.4%, change -0.8pp. Stable
Cash Flow Quality
CFFO/NI = 1.11. Profits backed by cash
FCF $3.8B, FCF/NI = 0.84
Accruals ratio = -1.2%. Low accruals
Cash $8.6B covers debt $2.7B
Balance Sheet Health
Goodwill+Intangibles $1.3B = 4% of equity. Manageable
Debt/EBITDA = 0.5x. Healthy
Other assets grew 60.3% vs revenue 1.0%
No write-off data
Acquisition Risk
FCF after acquisitions positive
Goodwill+Intangibles change 9% YoY. Normal
Manipulation Score
M-Score = -2.54 (< -2.22). Unlikely manipulator
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-08